Related Experiment Videos
Biopharmaceutical aspects of ritodrine retard in pregnant women
G G Essed1, H A Struyker Boudier, J A Van Zijl
1Department of Obstetrics and Gynaecology, Academic Hospital, State University of Limburg, Maastricht, The Netherlands.
Biopharmaceutical aspects of the new sustained-release formulation of ritodrine, a tocolytic agent, were studied in 9 patients with preterm labour. A mean bioavailability of 26% (range 22%-32%) was estimated after the 4th day of treatment (steady state). A.U.C.'s from oral administration were found to correlate well with those measured in i.v. therapy in the same patients (r = 0.92; p = 0.0004). It was concluded that differences in bioavailability of ritodrine-retard are small enough to enable clinicians, using this sustained release preparation, to make fair estimations of the oral dosage, needed to replace the initial i.v. treatment.
Biopharmaceutical aspects of the new sustained-release formulation of ritodrine, a tocolytic agent, were studied in 9 patients with preterm labour. A mean bioavailability of 26% (range 22%-32%) was estimated after the 4th day of treatment (steady state). A.U.C.'s from oral administration were found to correlate well with those measured in i.v. therapy in the same patients (r = 0.92; p = 0.0004). It was concluded that differences in bioavailability of ritodrine-retard are small enough to enable clinicians, using this sustained release preparation, to make fair estimations of the oral dosage, needed to replace the initial i.v. treatment.